USD 2.16
(-8.86%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -30.46 Million USD | 39.36% |
2022 | -36.39 Million USD | -38.05% |
2021 | -23.98 Million USD | 0.37% |
2020 | -23.78 Million USD | 39.94% |
2019 | -39.74 Million USD | -35.51% |
2018 | -29.47 Million USD | -192.38% |
2017 | -10.18 Million USD | 9.39% |
2016 | -11.56 Million USD | 17.61% |
2015 | -13.5 Million USD | 9.76% |
2014 | -14.87 Million USD | 2.53% |
2013 | -15.59 Million USD | -36.42% |
2012 | -9.79 Million USD | -32.02% |
2011 | -9.22 Million USD | 17.8% |
2010 | -10.36 Million USD | 39.61% |
2009 | -16.66 Million USD | -34.36% |
2008 | -13.43 Million USD | 16.04% |
2007 | -12.85 Million USD | -50.77% |
2006 | -8.76 Million USD | -104.79% |
2005 | -4.92 Million USD | 28.16% |
2004 | -6.86 Million USD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | -4.71 Million USD | 12.43% |
2024 Q2 | -5.41 Million USD | -19.47% |
2023 Q1 | -7.08 Million USD | -1.2% |
2023 Q4 | -5.37 Million USD | -99.26% |
2023 FY | - USD | 39.36% |
2023 Q2 | -9.04 Million USD | -27.74% |
2023 Q3 | -2.69 Million USD | 70.19% |
2022 Q2 | -8.35 Million USD | -18.26% |
2022 FY | - USD | -38.05% |
2022 Q3 | -10.57 Million USD | -26.56% |
2022 Q4 | -6.99 Million USD | 33.83% |
2022 Q1 | -7.06 Million USD | -4.82% |
2021 Q3 | -6.43 Million USD | -8.54% |
2021 Q4 | -6.74 Million USD | -4.79% |
2021 FY | - USD | 0.37% |
2021 Q1 | -5.53 Million USD | 2.23% |
2021 Q2 | -5.92 Million USD | -7.09% |
2020 Q2 | -5.65 Million USD | 0.0% |
2020 FY | - USD | 39.94% |
2020 Q1 | -5.65 Million USD | 46.89% |
2020 Q4 | -5.66 Million USD | 7.22% |
2020 Q3 | -6.1 Million USD | -7.85% |
2019 Q4 | -10.65 Million USD | 0.0% |
2019 FY | - USD | -35.51% |
2019 Q1 | -6.08 Million USD | 22.34% |
2019 Q2 | -6.08 Million USD | 0.0% |
2019 Q3 | -10.65 Million USD | -75.16% |
2018 Q4 | -7.82 Million USD | 0.0% |
2018 FY | - USD | -192.38% |
2018 Q1 | -6.73 Million USD | -5.77% |
2018 Q2 | -6.73 Million USD | 0.0% |
2018 Q3 | -7.82 Million USD | -16.23% |
2017 Q3 | -6.36 Million USD | -988.83% |
2017 Q2 | 716.5 Thousand USD | 0.0% |
2017 Q4 | -6.36 Million USD | 0.0% |
2017 Q1 | 716.5 Thousand USD | 132.37% |
2017 FY | - USD | 9.39% |
2016 Q4 | -2.21 Million USD | 0.0% |
2016 Q1 | -3.34 Million USD | 21.23% |
2016 Q3 | -2.21 Million USD | 33.92% |
2016 Q2 | -3.34 Million USD | 0.0% |
2016 FY | - USD | 17.61% |
2015 Q1 | -2.63 Million USD | 25.47% |
2015 Q3 | -4.25 Million USD | -61.17% |
2015 Q4 | -4.25 Million USD | 0.0% |
2015 FY | - USD | 9.76% |
2015 Q2 | -2.63 Million USD | 0.0% |
2014 Q2 | -3.96 Million USD | 0.0% |
2014 FY | - USD | 2.53% |
2014 Q4 | -3.54 Million USD | 0.0% |
2014 Q3 | -3.54 Million USD | 10.75% |
2014 Q1 | -3.96 Million USD | 1.26% |
2013 Q2 | -3.77 Million USD | 0.0% |
2013 FY | - USD | -36.42% |
2013 Q1 | -3.77 Million USD | -34.66% |
2013 Q3 | -4.01 Million USD | -6.28% |
2013 Q4 | -4.01 Million USD | 0.0% |
2012 Q2 | -2.74 Million USD | 0.0% |
2012 Q1 | -2.74 Million USD | -23.18% |
2012 Q3 | -2.87 Million USD | -4.69% |
2012 Q4 | -2.8 Million USD | 2.41% |
2012 FY | - USD | -32.02% |
2011 Q1 | -2.23 Million USD | 17.64% |
2011 Q4 | -2.23 Million USD | 0.0% |
2011 FY | - USD | 17.8% |
2011 Q2 | -2.23 Million USD | 0.0% |
2011 Q3 | -2.23 Million USD | 0.0% |
2010 Q4 | -2.7 Million USD | 0.0% |
2010 Q2 | -2.7 Million USD | 0.0% |
2010 Q3 | -2.7 Million USD | 0.0% |
2010 Q1 | -2.7 Million USD | 47.06% |
2010 FY | - USD | 39.61% |
2009 Q1 | -5.11 Million USD | -44.34% |
2009 Q3 | -5.11 Million USD | 0.0% |
2009 FY | - USD | -34.36% |
2009 Q4 | -5.11 Million USD | 0.0% |
2009 Q2 | -5.11 Million USD | 0.0% |
2008 Q2 | -3.54 Million USD | 0.0% |
2008 Q4 | -3.54 Million USD | 0.0% |
2008 Q1 | -3.54 Million USD | 2.53% |
2008 Q3 | -3.54 Million USD | 0.0% |
2008 FY | - USD | 16.04% |
2007 Q3 | -3.63 Million USD | 0.0% |
2007 FY | - USD | -50.77% |
2007 Q4 | -3.63 Million USD | 0.0% |
2007 Q1 | -3.63 Million USD | -49.56% |
2007 Q2 | -3.63 Million USD | 0.0% |
2006 Q3 | -2.43 Million USD | 0.0% |
2006 Q2 | -2.43 Million USD | 0.0% |
2006 Q1 | -2.43 Million USD | -91.74% |
2006 FY | - USD | -104.79% |
2006 Q4 | -2.43 Million USD | 0.0% |
2005 FY | - USD | 28.16% |
2005 Q2 | -1.26 Million USD | 0.0% |
2005 Q3 | -1.26 Million USD | 0.0% |
2005 Q1 | -1.26 Million USD | 27.97% |
2005 Q4 | -1.26 Million USD | 0.0% |
2004 Q4 | -1.76 Million USD | 0.0% |
2004 Q2 | -1.76 Million USD | 0.0% |
2004 Q3 | -1.76 Million USD | 0.0% |
2004 Q1 | -1.76 Million USD | 0.0% |
2004 FY | - USD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Bionano Genomics, Inc. | -213.6 Million USD | 85.736% |
Prenetics Global Limited | -47.89 Million USD | 36.387% |
Star Equity Holdings, Inc. | -1.68 Million USD | -1706.046% |
CareDx, Inc | -89.65 Million USD | 66.017% |
Exact Sciences Corporation | 41.87 Million USD | 172.758% |
Exagen Inc. | -19.15 Million USD | -59.077% |
Inotiv, Inc. | -26.5 Million USD | -14.948% |
Guardant Health, Inc. | -433.3 Million USD | 92.968% |
Biodesix, Inc. | -37.1 Million USD | 17.883% |
BioNexus Gene Lab Corp. | -2.48 Million USD | -1125.997% |
Precipio, Inc. | -4.31 Million USD | -605.604% |
iSpecimen Inc. | -9.1 Million USD | -234.676% |
Natera, Inc. | -383.27 Million USD | 92.051% |
Aspira Women's Health Inc. | -16.49 Million USD | -84.755% |
Standard BioTools Inc. | -54.45 Million USD | 44.051% |
23andMe Holding Co. | -291.87 Million USD | 89.561% |
Castle Biosciences, Inc. | -45.02 Million USD | 32.329% |
Personalis, Inc. | -96.8 Million USD | 68.527% |
Aclaris Therapeutics, Inc. | -117.56 Million USD | 74.084% |
Applied DNA Sciences, Inc. | -9.59 Million USD | -217.671% |
OpGen, Inc. | -29.51 Million USD | -3.243% |
T2 Biosystems, Inc. | -43.87 Million USD | 30.557% |
Myriad Genetics, Inc. | -67.8 Million USD | 55.062% |
ICON Public Limited Company | 1.63 Billion USD | 101.867% |
NeoGenomics, Inc. | -17.6 Million USD | -73.045% |
Star Equity Holdings, Inc. | -1.68 Million USD | -1706.046% |
IDEXX Laboratories, Inc. | 1.21 Billion USD | 102.502% |
RadNet, Inc. | 292.78 Million USD | 110.406% |
Psychemedics Corporation | -251 Thousand USD | -12038.645% |
Illumina, Inc. | -608 Million USD | 94.989% |
Check-Cap Ltd. | -17.64 Million USD | -72.633% |
Twist Bioscience Corporation | -176.7 Million USD | 82.758% |
DarioHealth Corp. | -53.49 Million USD | 43.044% |
Fulgent Genetics, Inc. | -46.55 Million USD | 34.551% |
Sera Prognostics, Inc. | -35.28 Million USD | 13.657% |
ENDRA Life Sciences Inc. | -9.78 Million USD | -211.381% |
OPKO Health, Inc. | -65.51 Million USD | 53.495% |
Medpace Holdings, Inc. | 363.15 Million USD | 108.39% |
Neogen Corporation | 182.59 Million USD | 116.686% |
Intelligent Bio Solutions Inc. | -8.81 Million USD | -245.807% |
Prenetics Global Limited | -47.89 Million USD | 36.387% |
Mainz Biomed B.V. | -25.01 Million USD | -21.817% |
bioAffinity Technologies, Inc. | -7.62 Million USD | -299.355% |
Trinity Biotech plc | -24.09 Million USD | -26.434% |
Neuronetics, Inc. | -22.75 Million USD | -33.872% |
Sotera Health Company | 514.14 Million USD | 105.926% |
bioAffinity Technologies, Inc. | -7.62 Million USD | -299.355% |